MLTX vs. ^GSPC

In the year-to-date period, MLTX achieves a -25.80% return, which is significantly lower than ^GSPC's -0.64% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MLTX Sharpe Ratio is -0.04, which is lower than the ^GSPC Sharpe Ratio of 0.61. The chart below compares the historical Sharpe Ratios of MLTX and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

The maximum MLTX drawdown since its inception was -64.60%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for MLTX and ^GSPC. For additional features, visit the drawdowns tool.

MoonLake Immunotherapeutics (MLTX) has a higher volatility of 14.44% compared to S&P 500 (^GSPC) at 6.29%. This indicates that MLTX's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.